MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-16-2026
Zomedica Corp. Market Cap 2011-2026 | ZOM
As of March 17, 2026 Zomedica Corp. has a market cap of $ 98 M
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap Zomedica Corp.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 137 M | 245 M | 297 M | 335 M | 25.9 M | 80.6 M | 175 M | 200 K | 200 K | 68 K | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 335 M | 68 K | 130 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Drug manufacturers industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aurora Cannabis
ACB
|
915 M | $ 3.45 | 0.58 % | $ 86.3 M |  Canada |
 |
Alimera Sciences
ALIM
|
101 M | - | - | $ 142 M |  USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
18 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
325 M | - | - | $ 754 M | USA |
 |
AcelRx Pharmaceuticals
ACRX
|
22.2 M | - | 7.5 % | $ 6.35 M | USA |
 |
Canopy Growth Corporation
CGC
|
142 M | $ 1.02 | - | $ 110 M | Canada |
 |
Agile Therapeutics
AGRX
|
1.29 M | - | 10.11 % | $ 58.2 M | USA |
 |
Cronos Group
CRON
|
3.63 B | $ 2.54 | 1.6 % | $ 1.33 B | Canada |
 |
Assertio Holdings
ASRT
|
75.4 M | $ 11.77 | 1.99 % | $ 836 M | USA |
 |
DURECT Corporation
DRRX
|
31.8 M | - | - | $ 50.1 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
717 M | - | - | $ 2.06 B |  France |
 |
Eagle Pharmaceuticals
EGRX
|
340 M | - | -39.89 % | $ 27.7 M | USA |
 |
Evolus
EOLS
|
271 M | $ 5.04 | 0.6 % | $ 325 M | USA |
 |
Evoke Pharma
EVOK
|
2.24 M | - | - | $ 36.6 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
966 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
89 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Catalent
CTLT
|
10.9 B | - | - | $ 11.5 B | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
88.6 M | $ 3.06 | 0.66 % | $ 43 M | USA |
 |
Jupiter Wellness
JUPW
|
82.8 M | - | - | $ 33.6 M | USA |
 |
Athenex
ATNX
|
11.4 M | - | -23.39 % | $ 1.76 M | USA |
 |
Endo International plc
ENDP
|
68.2 M | - | - | $ 28.9 M |  Irlanda |
 |
Harrow Health
HROW
|
1.93 B | $ 34.91 | 2.38 % | $ 1.28 B | USA |
 |
Emergent BioSolutions
EBS
|
139 M | $ 8.33 | 3.22 % | $ 426 M | USA |
 |
OrganiGram Holdings
OGI
|
382 M | $ 1.42 | 0.71 % | $ 402 M | Canada |
 |
China Pharma Holdings
CPHI
|
4.54 M | $ 0.62 | 2.94 % | $ 10.8 M |  China |
 |
Sundial Growers
SNDL
|
889 K | $ 1.44 | -4.64 % | $ 3.37 M | Canada |
 |
Organogenesis Holdings
ORGO
|
415 M | $ 2.58 | -2.27 % | $ 340 M | USA |
 |
Pacira BioSciences
PCRX
|
1.18 B | $ 22.69 | -2.45 % | $ 1.05 B | USA |
 |
ProPhase Labs
PRPH
|
131 M | - | - | $ 5.07 M | USA |
 |
Lannett Company
LCI
|
39.4 M | - | 1.15 % | $ 7.11 M | USA |
 |
Radius Health
RDUS
|
378 M | - | - | $ 1.42 B | USA |
 |
Perrigo Company plc
PRGO
|
1.96 B | $ 9.72 | 4.4 % | $ 1.35 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
1.72 M | - | - | $ 193 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
3.66 M | $ 2.4 | -2.24 % | $ 2.98 M | USA |
 |
Relmada Therapeutics
RLMD
|
162 M | $ 6.18 | 4.57 % | $ 186 M | USA |
 |
Rockwell Medical
RMTI
|
35.5 M | $ 0.96 | 6.61 % | $ 22.4 M | USA |
 |
PetIQ
PETQ
|
396 M | - | 1.64 % | $ 400 M | USA |
 |
OptiNose
OPTN
|
192 M | - | - | $ 1.08 B | USA |
 |
PLx Pharma
PLXP
|
118 M | - | -27.8 % | $ 2.56 M | USA |
 |
SCYNEXIS
SCYX
|
37.9 M | $ 0.9 | 4.68 % | $ 44.9 M | USA |
 |
Recro Pharma
REPH
|
133 M | - | -4.76 % | $ 65.3 M | USA |
 |
TherapeuticsMD
TXMD
|
23.9 M | $ 2.17 | - | $ 22.7 M | USA |
 |
Solid Biosciences
SLDB
|
226 M | $ 7.48 | 2.33 % | $ 305 M | USA |
 |
Veru
VERU
|
108 M | $ 2.37 | -0.84 % | $ 320 M | USA |
 |
Tilray
TLRY
|
1.19 B | $ 6.9 | 0.15 % | $ 4.26 B | Canada |
 |
Viatris
VTRS
|
18.4 B | $ 13.51 | - | $ 16.2 B | USA |
 |
Tricida
TCDA
|
359 M | - | - | $ 3.25 M | USA |
 |
cbdMD
YCBD
|
1.68 M | $ 0.72 | 1.41 % | $ 3.11 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
18.8 M | - | - | $ 55.5 M | USA |